Candel Shares Fall on Wider Loss From Operation, FDA Discussion
By Natalie Weger
Shares of Candel Therapeutics fell after the company posted a wider loss from operations and said it's in ongoing dialogue with the Food and Drug Administration about a license application.
Shares dropped 38% to $5.15 in after-hours trading on Thursday. The stock was down 9% through market-close, and is up 49% this year.
The biopharmaceutical company on Thursday posted a third-quarter loss from operations of $23 million or 28 cents a share, compared with a loss of $13.2 million, or 21 cents, the year earlier.
Operating expenses nearly doubled to $23 million from $13.2 million the year before.
Candel said it's still in talks with the FDA about a biologics license application for aglatimagene treatment in prostate cancer. The company plans to submit the application in the middle of 2027 depending on the result of that dialogue.
Write to Natalie Weger at natalie.weger@wsj.com.
(END) Dow Jones Newswires
November 12, 2026 18:23 ET (23:23 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
3 of the Best Core Stocks to Own
3 Great New ETFs From 2026
The 10 Best Companies to Invest in Now
United States